2025 Mississippi Medical Cannabis Market Reflections: Observations, Analysis, and Outlook
William Chism, CEO of River Remedy
Dear Readers,
Last year’s market reflection was written in the aftermath of a genuine shock. In early 2024, a testing-driven recall sidelined over half of Mississippi’s medical cannabis inventory, forcing operators and regulators alike to confront the fragility of a young market.
2025 offered no such excuse.
There was no sweeping market-wide event that reset the board overnight. No single regulatory surprise that operators could point to as the sole reason for exits, retrenchment, or consolidation. Instead, the year unfolded with relative stability.
And yet, consolidation accelerated anyway.
That fact tells us far more about the state of Mississippi’s medical cannabis market than any headline or quarterly statistic ever could. It suggests that the market is no longer being shaped by episodic disruption, but by economic gravity.
At River Remedy, we operate across the full medical cannabis value chain—cultivation, processing, wholesale, logistics, and retail. In 2025, we expanded our retail footprint to five dispensaries across the state, including locations that give us direct visibility into patient behavior from the Gulf Coast to North MS. That geographic reach, combined with our vertically integrated operations, allows us to see how regulatory decisions and operational realities interact across the entire cannabis ecosystem. It also forces us to confront the difference between theory and practice.
What follows is an attempt to describe what we observed in 2025, why it matters, and what it suggests about where Mississippi’s medical cannabis program is headed next.
1. Checking Our Receipts: What We Predicted vs. What Happened
Before offering new analysis, it is worth revisiting what we said twelve months ago. Predictions are easy to make and easier to forget. Accountability requires returning to them.
Patient retention would be the defining challenge. In December 2024, we estimated annual patient attrition at roughly 35% and warned that the market could not sustain itself on acquisition alone. We called for simplified renewals and reduced administrative friction. The market did not undergo any significant reform in this area. This year, using the same analytical framework applied to a larger dataset, we estimate annual attrition has risen to 45–50%. The problem we identified did not resolve itself — it worsened. More to come on this dynamic below.
Overcapacity would persist for years. We said this wasn’t a temporary blip but a structural reality. Confirmed—and then some. Much of Mississippi’s licensed cultivation capacity now sits dormant, with some of the large operators who still remain running at fractions of their theoretical output. But the nuance matters: there remains strong demand for excellent flower and low demand for cheap, subpar products. Overcapacity is not uniform; it is most severe for operators who cannot differentiate on quality.
Consolidation was inevitable. We framed consolidation as natural market evolution, not system failure. In 2025, that prediction accelerated—without the excuse of a crisis to blame. Independent dispensaries sold to larger groups. Chains acquired other chains. Smaller operators exited entirely. Today, a substantial majority of retail activity is concentrated among a small number of operating groups. We believe 70%+ of all retail market share is controlled by 10 retail consortiums.
Price wars would erode margins without building loyalty. We warned against the race to the bottom. In 2025, particularly on the Gulf Coast, we watched it unfold exactly as predicted. Medium-sized chains engaged in aggressive discounting to survive, conditioning patients to hunt for deals rather than build dispensary loyalty. Other operators adopted a different tactic: marking up products beyond the standard 2–2.5x, then advertising steep discounts that merely returned prices to normal. Patients caught on. Now when a dispensary advertises “40% off,” patients expect a true 40%—and feel deceived when they don’t get it. Discounting did not create lasting competitive advantages; it created complications. Patients have now been conditioned to wait for the next sale rather than buy consistently, and operators who lack control over their own supply chain may come to regret the long‑term effects of this dynamic.
Compliance would become table stakes. The most significant compliance change entering 2025 involved flower and pre-roll testing standards, which introduced tighter thresholds for total yeast and mold. While aggressive, these standards were not unprecedented—they aligned with requirements in other mature cannabis markets and were adopted in the name of public health and patient safety. Operators had nearly a year to prepare.
We argued that operators who treated compliance as strategy—not just obligation—would lead. The sterilization debate proved the point.
Here is the reality: clean, safe sterilization technology exists that eliminates yeast and mold before flower ever reaches the testing lab. The process is well-established, does not degrade product quality when applied correctly, and is used routinely in other states with strict testing standards. It is, in effect, insurance—a process step that dramatically reduces the risk of failed tests, administrative holds, and destroyed inventory.
Yet at the beginning of 2025, a subset of operators remained skeptical of sterilization—questioning its necessity, its cost, or its impact on product integrity. Much of this resistance was philosophical, and some of the rhetoric overstated the risks.
By year-end, those same operators were lining up for sterilization services. The economics made the decision for them—rising testing failures and disposal costs left little room for ideology. The “sky is falling” scenario never materialized. Product quality did not collapse. Patients did not revolt. The system absorbed the change.
Standards rose. Behavior adjusted. Compliance is no longer a debate—it is the cost of entry. That is exactly what maturation looks like.
Intoxicating hemp posed a significant threat. We called for fair regulation and enforcement. We fought for sensible reform throughout 2025. The legislative outcome was incomplete—no clean statutory resolution emerged. But enforcement action throughout the year began to change the retail environment, and late-year federal legislation addressed the core loophole.
To be clear: this is not an overnight victory for the licensed medical market. Hemp shops are still winding down operations—some gracefully, others not. The national fight is far from over, and implementation will determine whether the federal ban has real teeth. More importantly, we have not seen evidence that former hemp consumers have migrated to licensed dispensaries in meaningful numbers. The patients who were buying unregulated products were often doing so because of price, convenience, or because they did not qualify for the medical program. Closing the hemp loophole does not automatically convert those consumers into medical patients.
Overall, though, the landscape has improved. The threat has not vanished. But we also recognize that enforcement alone will not grow the medical market. That responsibility falls to us.
It is on licensed operators to educate potential patients about what the medical program actually offers: products that are tested, regulated, and consistent. Products where you know exactly what you are getting—the strain, the potency, the source. Products held to safety standards that unregulated alternatives never had to meet. When you account for quality, reliability, and peace of mind, the medical program is not just safer—it is better value.
That case will not make itself. We are making it—every day, one patient at a time.
2. The Quiet Shift: From Novelty to Reliability
Early cannabis markets incentivize novelty. When a program is new, “new” itself is a strategy.
For much of 2023 and early 2024, differentiation often meant experimentation. Operators searched for traction by asking a simple question: What else can we put THC into? Some of those experiments worked. Many failed. Across the state, remnants of that phase still exist in the form of slow-moving, obscure products that never found sustained demand.
In 2025, patient behavior pivoted.
Patients—particularly the pragmatic, adult patient base that defines Mississippi’s program—began optimizing for reliability. They stopped looking for the newest gimmick and started looking for products that work, are consistently available, and do not require them to gamble scarce allotment units on an unknown outcome.
Reliability is not exciting. It does not show up as a “launch.” It manifests in boring fundamentals: disciplined SKUs, predictable production, clean inventory, and systems that reduce friction.
At River Remedy, we saw this shift reflected directly in our sales data. Our top-performing products were not new introductions—they were established SKUs with consistent quality and reliable availability. Patients stopped experimenting with their allotment and started allocating it to products they trusted.
As markets mature, consistency becomes more valuable than novelty. That transition favors a specific type of operator: one built for repetition, not improvisation.
3. Consolidation Without Crisis
In 2024, it was easy to attribute consolidation to the recall or regulatory pressure. In 2025, that explanation vanished, yet the trend intensified.
We observed consolidation across every layer of the market: independent dispensaries selling to larger operators, chains acquiring other chains, and smaller operators choosing to exit entirely. Today, a substantial majority of retail activity is concentrated among a small number of operating groups. The top 5 retail groups account for ~60% of retail market share, with the top ten accounting for ~70-75%.
This outcome is not evidence of a broken system. It is the arithmetic of a competitive market where execution, capital discipline, and cost structure determine survival.
River Remedy participated in this consolidation deliberately. We acquired two additional retail locations in 2025, bringing our total to five dispensaries across the state. This was not expansion for its own sake. Each acquisition was evaluated against a specific thesis: Does this location give us better geographic coverage, patient access, and market intelligence? Does the operation meet our standards, or can it be brought to them efficiently?
The result is a retail footprint that spans Mississippi—from our Corinth location in the north, which Leafly recognized as the top dispensary in the state, to stores serving the central corridor and coastal markets. That breadth is not a vanity metric. It is an intelligence network. We see how patient preferences vary by region, how pricing pressures manifest differently in different markets, and how operational challenges compound or resolve depending on local conditions.
In 2025, we strengthened that network with the addition of Herbal Alchemy—one of Mississippi’s original dispensaries, celebrated for its locally tailored patient care and the longevity and tenure of its core team. Our role was not to replace their momentum, but to support it and build upon it. On the Gulf Coast, we took over a Gulfport location that had already changed hands once before and brought it back to fundamentals with a talented team. These were not cosmetic changes; they were strategic additions that reinforced the depth and diversity of our retail presence.
For operators still evaluating whether to consolidate, acquire, or exit: the window for favorable terms is narrowing. The buyers with capital and operational capacity are becoming more selective. The calculus that made sense in early 2025 may not hold in late 2026.
4. Vertical Integration: Owning the Liability
There is often a debate in cannabis about which model wins: the fully integrated vertical operator or the focused specialist. Our observation in 2025 is that there is no single right answer—only right execution.
At River Remedy, we are vertically integrated by design—and not in the nominal sense that many operators claim. We are the only operator in Mississippi with significant scale at every stage of the value chain: cultivation, processing, wholesale distribution, and retail. We are a major producer in every category we compete in.
Over the past three years, we have built both a leading retail platform—five dispensaries spanning the state, including Leafly’s top-rated dispensary in Mississippi—and the most widely distributed wholesale operation in the market. Our products are on shelves in dispensaries we don’t own because they earn that placement. That dual presence is not an accident; it is the result of disciplined execution across every function, repeatedly, under real market pressure. Experience compounds.
For River Remedy, owning the supply chain is about owning the inputs. It allows us to control quality from the soil to the shelf, ensuring that the product we promise is the product the patient receives. It also gives us total data fidelity—we don’t have to guess why a product is selling or failing; we can trace the signal all the way back to the cultivation room. When we see movement at one of our five dispensaries, we can adjust production decisions within days because we control the entire pipeline.
But vertical integration also removes excuses. If our flower underperforms, we cannot blame a supplier. If our edibles underperform, the issue traces directly to our process. Vertical integration is not just a defensive moat—it is an offensive tool that demands operational excellence at every stage. The shelf is a meritocracy, and structure does not change that.
What 2025 punished was not any particular structure—it was mediocrity.
5. Patient Data: Growth, Attrition, and the Friction Beneath the Surface
The good news first: Mississippi’s medical cannabis program continues to grow. Active patients increased by approximately 32% year over year, rising from just under 50,000 at the end of 2024 to just above 66,000 today. Total card registrations grew by approximately 52% over the same period. Growth has been consistent and predictable—a sign of a maturing program finding its footing.
But those two numbers—32% active growth versus 52% total registration growth—tell a more complicated story. The gap between them is attrition.
When we published this analysis in 2024, we estimated an annual attrition rate of roughly 35%. That number was high, but we attributed it largely to early-stage friction and process complexity. We urged policymakers to simplify renewals and reduce administrative burden.
This past year, the picture hardened.
Using the same analytical framework, we now estimate annualized attrition at 45–50%.
The Measurement: We analyzed a sample of approximately 3,000 patients, segmented by those who received their cards one year ago and those who received them six months ago. We evaluated how many remain active today. The result: of the patients who received their card one year ago, roughly 55% are active, and roughly 45% are inactive. While some patients renew under new card numbers, those edge cases are insufficient to explain the magnitude of the drop. Using a 1,000 card sample to understand the 6-month attrition rate, we observed a small fallout rate (sub 5%).
Growth Is Positive, But Decelerating: The market is not shrinking. Over the course of 2025, new card registrations grew at roughly 93 patients per day. But the trend line points downward: the first half of 2025 averaged approximately 98 cards per day; the second half fell to approximately 90 cards per day.
Attrition Drivers: The drivers of attrition remain clear: cost, timing, and the administrative burden of annual renewal. Our recommendation remains unchanged from last year: simplifying renewals is one of the single highest-leverage policy tools available to grow the market. We said it in 2024. We are saying it again.
6. The Allotment Change: Isolating the Signal from the Noise
The most discussed regulatory change of 2025 was the update to unit allotment calculations, particularly for edibles.
In 2024, we advocated for standardizing units based on total THC content and eliminating potency caps. We achieved part of that goal—the unit calculation changed. Potency caps remain.
It is tempting to look at 2025 retail data and ascribe every positive trend to this regulatory shift. However, honest analysis requires us to admit that isolating this variable is nearly impossible. Did edible sales improve because of the allotment change? Or did they improve because product quality rose, brands consolidated, or pricing on a per MG or per unit basis shifted?
The Fundamentals Matter More: When we look at the total revenue split—dollars per category—we did not see a revolution. Edibles crept up a few percentage points in Q3 and Q4 relative to the twelve months preceding the allotment change, but the shift was incremental, not dramatic. Revenue did not aggressively swing toward edibles overnight.
The change did expand access. For patients who previously couldn’t afford gummies—not necessarily because of price, but because the unit cost in MMCEUs made them an inefficient use of limited allotment—the math now works. That unlocked a segment of demand that was real but suppressed.
However, the allotment change did not lead to materially higher spend per patient. After a temporary bump in July and August—likely driven by the new unit availability and excitement about the more rational unit calculations—average monthly spend per active cardholder fell below $200 in Q4.
The allotment change removed friction. It did not create desire.
The Economic Offset: What we did observe was a shift in unit economics. Dollars per milligram of THC declined: patients got more potency for their dollar. Dollars per unit increased: producers captured more revenue per finished package. Packaging a 1,000 mg bag takes the same labor as packaging a 100 mg bag. Depending on your cost of THC (or biomass), these two effects largely offset one another – but we believe that this was a win-win for patients and producers alike. For the patient, the value proposition improved. For the producer, the revenue per labor-hour improved.
We expect higher-dose SKUs to persist, but we also predict this category will become crowded. As the novelty of “high dose” fades, we will return to the same differentiator that governs flower: consistency.
7. Compliance, Sterilization, and the End of the Panic Cycle
One of the quieter but more important developments of 2025 was the industry’s collective shift on compliance—particularly around sterilization and testing standards.
At the beginning of the year, these topics were still highly charged. There was no shortage of rhetoric about quality degradation, cost burdens, and existential threats to small operators. Much of that debate was framed ideologically rather than economically.
By the end of the year, the conversation had changed.
Sterilization has increasingly become what it actually is: insurance. Not a philosophical position, not a marketing angle—simply a rational response to asymmetric risk. When the downside of a failed test includes administrative holds, lost shelf space, delayed revenue, and reputational damage, the math becomes straightforward.
What 2025 made clear is that the economics settled the debate faster than the rhetoric. Many of the same operators who publicly criticized sterilization early on quietly adopted it once the economics became unavoidable. The “sky is falling” scenario never materialized. Product quality did not collapse. Patients did not revolt. The system absorbed the change.
From a regulatory perspective, this is a success story. Standards rose, behavior adjusted, and the market did not break. Compliance is no longer a debate topic; it is increasingly table stakes. That is exactly what maturation looks like.
8. Intoxicating Hemp, Federal Rescheduling, and the Limits of Policy Relief
Two federal developments in late 2025 will shape the cannabis landscape for years to come. They are often conflated in media coverage and industry discussion, but they address fundamentally different problems and carry different implications.
The Hemp Ban: Closing the Loophole
The intoxicating hemp category has been one of the most misunderstood forces in cannabis—not because it lacks impact, but because it is often discussed in absolutes.
In 2025, Mississippi’s legislative efforts to address intoxicating hemp products did not produce a clean statutory resolution. That outcome was widely viewed as a failure. In practice, it was less decisive than many expected, because what mattered more was enforcement. Throughout the year, clearer guidance and coordinated law-enforcement action began to change the retail environment in Mississippi. Many products that were unsafe, untested, and never intended to coexist with a medical program were removed from shelves where they did not belong. The effect was quiet but impactful.
Then, at the federal level, a more definitive step arrived.
The federal hemp ban, included in the year-end funding bill, addressed loopholes in the 2018 Farm Bill that had been exploited by actors who wanted to sell intoxicating cannabis products under the guise of hemp—avoiding the testing, safety, and regulatory requirements that licensed medical operators must meet. This was not a crackdown on hemp as an agricultural product. It was a correction to a statutory ambiguity that had allowed an unregulated parallel market to flourish.
For Mississippi’s medical program, the effect is constructive. Patients are less likely to encounter unregulated substitutes that undermine trust and safety. Licensed operators compete on a fairer field.
That said, the fight is not over. Implementation and enforcement will determine whether the federal ban has teeth. We will continue pressing for safe, tested, and regulated products for all consumers. This issue may return in various forms, and we intend to remain part of that conversation.
Rescheduling: A Different Problem, A Different Timeline
Separate from the hemp ban, the federal government moved to commence the rescheduling process via executive order—a step that had long been discussed but never initiated. This addresses a different problem entirely.
Rescheduling is not about intoxicating hemp or closing loopholes. It is about the federal government acknowledging what patients and practitioners have known for years: cannabis has legitimate medical benefits and is worthy of formal academic and scientific research. That acknowledgment matters. It opens pathways to traditional banking, institutional financing, and the kinds of capital structures that have been unavailable to cannabis operators regardless of their state-level compliance.
However, it is important to be realistic about timing. The rescheduling process is ongoing, not complete. Financial markets move cautiously, and meaningful changes in underwriting, lending, and custody will lag the policy shift by years, not months.
Lower taxes improve cash flow. They do not change cost structure discipline. Better access to banking improves operational efficiency. It does not create demand.
The most important point is this: federal policy tailwinds do not override local economic gravity.
Mississippi’s medical cannabis market will still be governed by the same forces that shaped 2025—supply and demand balance, capital efficiency, execution quality, and retail competence. Operators who struggle with those fundamentals will not be rescued by rescheduling. Operators who execute well will benefit incrementally, not exponentially.
In that sense, the late-year federal developments are best understood as long-term wins, not overnight lifelines. The benefits will compound over years as banking relationships normalize, capital costs decline, and the stigma that has kept institutional investors on the sidelines continues to erode. But none of that changes what operators must do tomorrow morning.
The market will not pause to wait for federal tailwinds to arrive. Operators who execute well will be positioned to capture the upside when it materializes. Operators who are struggling today will still be struggling then—just with slightly better banking options.
That is exactly how durable industries are built: policy relief that supports stability without replacing execution.
9. Overcapacity: The Geography of Mismatch
Mississippi continues to grapple with overcapacity in cultivation and processing—a structural reality we identified in 2024 (and 2023, and 2022).
Many observers view this as a crisis. We view it as the mechanism of price discovery.
But the story is more nuanced than “too much supply.” What we observed in 2025 was mismatch, not uniform excess.
Some operators are capacity-constrained, struggling to keep up with demand, running full rooms, and delaying expansion due to capital or infrastructure limits. Others are operating far below capacity, idling rooms, cutting shifts, and waiting for demand that may never arrive for their products.
This coexistence is not a contradiction. It is a market inefficiency.
Capacity is not fungible. Location, product quality, operational competence, and relationships determine whether square footage is valuable or stranded. Two facilities with identical licenses can experience entirely different realities. The facility producing excellent flower at competitive cost is sold out. The facility producing mediocre flower at bloated cost is sitting on inventory.
The implication is important: contraction alone will not “fix” overcapacity. What the market requires is reallocation—capital and capacity flowing toward operators who can actually deploy it productively.
Overcapacity forces discipline. If you cannot grow profitably at current market prices, you do not just have a pricing problem; you have a cost structure problem. The winners in this environment are not the ones waiting for supply to contract so prices can rise. The winners are the ones re-engineering their operations to function profitably at today’s clearing price.
Markets resolve this inefficiency over time, but rarely gently.
10. Discounting, Price Wars, and the Illusion of Strategy
One of the most destructive habits to emerge in oversupplied markets is the belief that discounting is a strategy.
It isn’t. It is a reaction.
In 2025, aggressive discounting became increasingly visible as operators competed for patient traffic. The pattern was most pronounced on the Gulf Coast, where chains engaged in pricing battles that compressed margins across the entire local market. The short-term result was increased unit sales. The medium-term result was patients trained to wait for deals, reduced profitability for all participants, and strained relationships with wholesale partners whose products were being devalued.
We also observed a more cynical variant: operators marking up products beyond standard margins, then advertising dramatic discounts that merely returned prices to normal. Patients caught on. The result is an erosion of trust that extends beyond the offending dispensaries to the category as a whole. When a patient sees “40% off” and receives something closer to standard pricing, they learn to grow more wary of promotional claims.
Discounting does not necessarily build loyalty. It trains customers to wait.
The most telling sign of market maturity is that the strongest operators did not lead the price wars. They focused on consistency, education, and availability—allowing others to burn margin in pursuit of volume that could not be sustained.
Price is easy to copy. Trust is not.
11. Capital Efficiency and the “Quiet Failure”
One of the defining characteristics of 2025 was the nature of business failure.
In early years, failures can be loud. In 2025, most failures were quiet.
Operators with overbuilt footprints or misaligned cost structures didn’t always explode; they often just faded. They cut shifts. They reduced SKUs. They quietly shopped assets. They entered receivership and emerged smaller.
This “quiet failure” is a sign of a market learning to price risk. It is also a warning: capital efficiency is not optional.
Revenue is easy to buy through discounting. Profit is hard to earn. We saw competitors chase top-line revenue numbers that looked impressive on a slide deck but were disastrous on a P&L. In a capital-constrained environment, those strategies have a short half-life.
The operators who survived 2025 in strong position were not necessarily the largest or the most well-funded. They were the ones who understood that in a market with compressed margins, every dollar of waste is a dollar you cannot afford.
12. Looking Ahead: Why 2026 Will Force Rational Exits
Looking forward, we expect consolidation to continue—but in a quieter, more deliberate form.
The next wave of exits is unlikely to be driven by crisis. It will be driven by calculus.
Many middle-of-the-road operators will look at the effort required to compete—capital investment, operational complexity, compliance burden, margin pressure—and conclude that the return profile no longer justifies the risk. The house is not on fire. But the upside is no longer compelling enough.
These exits will not look like failures. They will look like decisions.
For policymakers and industry participants alike, this is not a sign of weakness. It is how competitive markets mature. The goal is not to preserve every operator. It is to preserve a system that delivers safe, reliable products to patients.
2026 will reward operators who embrace that reality—and punish those who mistake endurance for inevitability.
13. The Strategy of Boring Excellence
If I had to summarize our outlook for 2026, it is that the era of “cleverness” is over.
The next phase of the Mississippi market will not be won by the operator with the most novel idea, the wildest marketing claims, or the most complex financial engineering.
It will be won by boring excellence.
Repeatability: Can you put the same bag of gummies on the shelf, with the same quality, 52 weeks a year?
Discipline: Can you say “no” to SKU proliferation and focus on the 20% of products that drive 80% of margin?
Systems: Can you operate with clean data that allows for decision-making based on reality, not intuition?
The early years of a market are defined by possibility. The middle years are defined by reality. In 2025, reality asserted itself.
That is progress.
Final Thoughts
Mississippi’s medical cannabis market is no longer new. It is no longer fragile in the way it once was. But it is also not yet stable.
We are in the middle passage—past the chaos of inception, not yet at the equilibrium of maturity. This is the phase where the operators who will define the next decade separate themselves from those who were merely present for the first few years.
At River Remedy, we are building for that future. Not because we assume we will win, but because we understand what winning requires: relentless focus on quality, disciplined capital allocation, systems that scale, and a commitment to patients that transcends quarterly metrics.
We have been right about more than we have been wrong about. We intend to stay that way.
The work continues.
With conviction,
William Chism
CEO, River Remedy